Dr George A Lussier, MD in Haverhill, MA - Family Medicine

Dr George A Lussier, MD is a Family Medicine physician based in Haverhill, Massachusetts. Dr George A Lussier is licensed to practice in Massachusetts (license number 33830) and his current practice location is 1 Merrimack St, Haverhill, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (978) 521-6555.

NPI number for Dr George A Lussier is 1447348255 and his current mailing address is 1 Merrimack St, Haverhill, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1447348255.

Contact Information

	Dr George A Lussier, MD
	1 Merrimack St, Haverhill, MA 01860
	(978) 521-6555
	Not Available

Physician's Profile

Full Name	Dr George A Lussier
Gender	Male
Speciality	Family Medicine
Location	1 Merrimack St, Haverhill, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1447348255
Provider Enumeration Date: 10/10/2006
Last Update Date: 04/28/2015

Medical Identifiers

Medical identifiers for Dr George A Lussier such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1447348255	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	33830 (Massachusetts)	Primary
207R00000X	Internal Medicine	33830 (Massachusetts)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr George A Lussier is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr George A Lussier, MD 1 Merrimack St, Haverhill, MA 01860 Ph: (978) 521-6555	Dr George A Lussier, MD 1 Merrimack St, Haverhill, MA 01860 Ph: (978) 521-6555

News Archive

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

New model to test effectiveness of existing and potential CF therapies

UNC School of Medicine researchers have developed a new laboratory model of the infection- and inflammation-plagued airways of cystic fibrosis (CF) patients.

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

Focus on GHI principles necessary to ensure success of U.S. global health programs

Noting that the Global Health Initiative (GHI) leadership and the three core entities of GHI - USAID, the Centers for Disease Control and Prevention (CDC) and PEPFAR - announced the closure of the GHI office and an end to the initiative's current phase on July 3, Serra Sippel, president of the Center for Health and Gender Equity, writes in the Huffington Post's "Politics" blog that "the three agencies will be responsible for ensuring that the GHI principles are implemented in the field to achieve global health goals."

Re-introduction of rotavirus vaccine does not increase intussusception rates in the U.S.

The rotovirus vaccine was pulled from the marketplace in 1999 after being associated with painful gastrointestinal complications, however, the updated rotavirus vaccines do not appear to increase the occurrence of these potentially fatal side effects, according to a new study by child health experts at C.S. Mott Children's Hospital.

Family Medicine Doctors in Haverhill, MA

Dr. Peter L Rees, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 62 Brown Street, Suite 200, Haverhill, MA 01830 Phone: 978-521-8377 Fax: 978-521-3689
Renae Rochelle Mitchell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 62 Brown St. Suite 405, Haverhill, MA 01830 Phone: 978-521-8377 Fax: 978-521-3689
John Marshall King, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Park Way, Haverhill, MA 01830 Phone: 978-521-3200 Fax: 978-557-8798

Dr George A Lussier, MD - Family Medicine in Haverhill, MA